AI Transforms Sepsis Care With Faster, More Effective Treatments

Day Zero Diagnostics introduced Keynome gAST, a genomic testing method using AI to accelerate sepsis diagnosis by directly analyzing bacterial genomes from patient samples, potentially transforming treatment and reducing mortality. Researchers at Day Zero Diagnostics have developed Keynome gAST, an AI-driven genomic Antimicrobial Susceptibility Test that quickly predicts antimicrobial resistance by analyzing bacterial genomes from blood samples. This breakthrough, demonstrated at ASM Microbe, could drastically improve sepsis diagnosis and treatment, speeding up decision-making and potentially saving lives amidst increasing antimicrobial resistance.

Sepsis is a life-threatening infection complication and accounts for 1.7 million hospitalizations and 350,000 deaths annually in the U.S.

Fast and accurate diagnosis is critical, as mortality risk increases up to 8% every hour without effective treatment. However, the current diagnostic standard is reliant on culture growth, which typically takes 2-3 days. Doctors may choose to administer broad-spectrum antibiotics until more information is available for an accurate diagnosis, but these can have limited efficacy and potential toxicity to the patient.

Innovative AI Approach in Diagnostics In a study presented at ASM Microbe, a team from Day Zero Diagnostics unveiled a novel approach to antimicrobial susceptibility testing using artificial intelligence (AI). Their system, Keynome gAST, or genomic Antimicrobial Susceptibility Test, by.